Literature DB >> 9655855

Detailed mapping of ochratoxin A reabsorption along the rat nephron in vivo: the nephrotoxin can be reabsorbed in all nephron segments by different mechanisms.

A Dahlmann1, W H Dantzler, S Silbernagl, M Gekle.   

Abstract

Ochratoxin A (OTA) is a widespread nephrotoxin excreted to a substantial degree via the kidney. Previously we showed that [3H]OTA can be reabsorbed along the rat nephron in vivo (Zingerle et al., 1997). In this study we investigated in detail the contribution of different nephron segments to [3H]OTA reabsorption and determined the possible mechanisms involved by microinfusion and microperfusion experiments. At pH 6 (approximately 94% of OTA neutral), OTA is reabsorbed in all nephron segments investigated. The estimated fractional reabsorptions (FR) at a tubular load of 20 fmol/min are: proximal convoluted tubule (PCT), 14.8%; proximal straight tubule (PST), 27.4%; ascending limb of Henle's loop (ALH), 13.6%; distal tubule (DT), 11.6%; collecting duct (CD), 24.6%; terminal CD, 22.0%. At pH 8 (approximately 10% of OTA neutral) FR are as follows: PCT, 0%; PST, 25.9%; ALH, 14.0%; DT, 3.2%; CD, 8.2%. Thus, OTA reabsorption in PST and ALH in pH-independent. Reabsorption in PST but not in DT or CD was inhibited by sulfobromophthalein, a substrate of the apical organic anion carrier. L-Phenylalanine did not reduce OTA reabsorption. After intravenous injection of unlabeled OTA, resulting in a plasma concentration of approximately 10(-5) mol/l, the FR of [3H]OTA during early proximal microinfusion was reduced slightly. From our results we conclude: 1) OTA can be reabsorbed in all nephron segments investigated. 2) Under physiological conditions the predominant sites of reabsorption are PST, ALH and terminal CD. 3) Reabsorption in PST and ALH is not pH-dependent. 4) pH-independent reabsorption in PST is mediated by the apical organic anion transporter (OAT-K1), whereas pH-dependent reabsorption in PCT is mediated by H(+)-dipeptide cotransporter(s). 5) Reabsorption also takes place during natural exposure, i.e., when OTA is present in plasma and renal tissue. 6) The high FR in ALH and CD explains, at least in part, the preferential impairment of postproximal functions and the accumulation in renal inner medulla and papila.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9655855

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

Review 1.  Xenobiotic transporters and kidney injury.

Authors:  Blessy George; Dahea You; Melanie S Joy; Lauren M Aleksunes
Journal:  Adv Drug Deliv Rev       Date:  2017-01-20       Impact factor: 15.470

2.  Effect of dietary sodium bicarbonate supplementation on the toxicokinetics of ochratoxin A in pigs.

Authors:  R Blank; S Wolffram
Journal:  Mycotoxin Res       Date:  2005-06       Impact factor: 3.833

Review 3.  Ochratoxin A and human health risk: a review of the evidence.

Authors:  Travis R Bui-Klimke; Felicia Wu
Journal:  Crit Rev Food Sci Nutr       Date:  2015       Impact factor: 11.176

4.  Molecular mechanism of ochratoxin a transport in the kidney.

Authors:  Naohiko Anzai; Promsuk Jutabha; Hitoshi Endou
Journal:  Toxins (Basel)       Date:  2010-06-09       Impact factor: 4.546

5.  Survey of slaughtered pigs for occurrence of ochratoxin A and porcine nephropathy in Serbia.

Authors:  Dragan Milićević; Verica Jurić; Srđan Stefanović; Milijan Jovanović; Saša Janković
Journal:  Int J Mol Sci       Date:  2008-11-07       Impact factor: 6.208

Review 6.  Metabolites of Microbial Origin with an Impact on Health: Ochratoxin A and Biogenic Amines.

Authors:  Pasquale Russo; Vittorio Capozzi; Giuseppe Spano; Maria R Corbo; Milena Sinigaglia; Antonio Bevilacqua
Journal:  Front Microbiol       Date:  2016-04-08       Impact factor: 5.640

Review 7.  Ochratoxin A: Molecular Interactions, Mechanisms of Toxicity and Prevention at the Molecular Level.

Authors:  Tamás Kőszegi; Miklós Poór
Journal:  Toxins (Basel)       Date:  2016-04-15       Impact factor: 4.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.